-+ 0.00%
-+ 0.00%
-+ 0.00%

BridgeBio Oncology Therapeutics shareholders elect Lebowitz, McCormick to board

PUBT·06/22/2026 20:06:31
Listen to the news
BridgeBio Oncology Therapeutics shareholders elect Lebowitz, McCormick to board
  • Bridgebio Oncology Therapeutics held its annual shareholder meeting on June 16, 2026.
  • Shareholders backed the selection of two directors to serve through the 2029 annual meeting.
  • Shareholders ratified Deloitte & Touche as independent registered public accounting firm for fiscal 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-277513), on June 22, 2026, and is solely responsible for the information contained therein.